{"id":{"repo_id":"dominican","oai_identifier":"oai:scholar.dominican.edu:masters-theses-1341"},"canonical_url":"https://search.dev.ndltd.org/etd/dominican/oai:scholar.dominican.edu:masters-theses-1341","repository":{"repo_id":"dominican","name":"Dominican University of California","base_url":"https://scholar.dominican.edu/do/oai/"},"display":{"title":"Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test","abstract":"<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.</p>","abstract_html":"&lt;p&gt;KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.&lt;/p&gt;","abstract_has_math":false,"creators":["Garcia, Manuel"],"institution":null,"degree_name":"Master of Science","degree_level":"Master's Thesis","degree_discipline":"Clinical Laboratory Sciences","degree_department":null,"school":null,"contributors":["Roberta M. Madej, PhD, CLS., MB(ASCP), MBA","Maria C. DeSousa, JD, MPA, CLS"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-05-01T07:00:00Z","date_published":"2018-05-01T07:00:00Z","updated_at":"2026-07-24T02:04:44Z","subjects":["Q-Clamp","Cell-Free DNA","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://scholar.dominican.edu/masters-theses/335","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Roberta M. Madej, PhD, CLS., MB(ASCP), MBA","Maria C. DeSousa, JD, MPA, CLS"]},{"key":"dc:creator","label":"Author","values":["Garcia, Manuel"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2018-05-08T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Clinical Laboratory Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Master's Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q-Clamp","Cell-Free DNA","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://scholar.dominican.edu/masters-theses/335"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.</p>"]},{"key":"dc:title","label":"Title","values":["Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test"]}]}],"canonical_facts":{"dc:contributor":["Roberta M. Madej, PhD, CLS., MB(ASCP), MBA","Maria C. DeSousa, JD, MPA, CLS"],"dc:creator":["Garcia, Manuel"],"dc:date.available":["2018-05-08T07:00:00Z"],"dc:description.abstract":["<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.</p>"],"dc:identifier":["https://scholar.dominican.edu/masters-theses/335"],"dc:subject":["Q-Clamp","Cell-Free DNA","Medicine and Health Sciences"],"dc:title":["Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test"],"thesis:degree_discipline":["Clinical Laboratory Sciences"],"thesis:degree_level":["Master's Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T02:04:44Z"}